natgillin/translations-raw huggingface dataset:
The aqueous solution according to claim 3, wherein the at least one flavouring agent is selected from any of the cherry, lemon, lime, mandarin, orange, tangerine, mint, strawberry, banana, caramel, liquorice, passion-fruit, peach, raspberry, tutti-frutti, grapefruit, vanilla, cream, chocolate, grape flavour or mixture thereof, and is present in an amount of from 0 to 5% w/V, e.g. 
Otopina prema patentnom zahtjevu 5, pri čemu je najmanje jedno sredstvo za poboljšanje okusa odabrano od bilo koje od aroma trešnje, limuna, limete, mandarine, narnače, mandarine, metvice, jagode, banane, karamele, sladića, krunica, breskve, maline, slatkiš od ražličitog voća, grejp, vanilije, vrhnje, čokolade, okus grožđa ili njihova smjesa, na primjer odabran od arome vanilije i jagode, i prisutan je u iznosu od 0 do 5% tež/vol, npr.
The aqueous solution according to claim 3, wherein the at least one viscosity increasing agent is selected from cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose, poloxamers, from gums, guar gum, tragacanthe gum, acacia gum, xanthane gum, gelane gums, alginic derivatives, alginic acid, sodium alginate, polyvinylpyrrolidone, from silicates, bentonite, laponite, veegum, more particularly from non-ionic poloxamers, polyvinylpyrrolidone and cellulose ethers, in an amount of from 0 to 15% w/V, e.g. 
Otopina prema bilo kojem od patentnih zahtjeva 5 do 7, pri čemu je najmanje jedno sredstvo za povećanje viskoznosti odabrano od derivata celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, od guma, guar gume, tragantove gume, gume akacije, ksantan gume, gelan gume, alginskih derivata, alginske kiseline, natrijum alginata, polivinilpirolidona, od silikata, bentonita, laponita, veegum, specifičnije od ne-ionskih poloksamera, polivinilpirolidona i celulozni eteri, u količini od 0 do 15% tež/vol, npr.
The aqueous solution according to anyone of claims 1 to 8, wherein the at least one non-sugar type sweetener is selected from saccharin, saccharin salts, sodium saccharin, calcium saccharin, sucralose, potassium acetosulfam, stevioside, steviol, mannitol, erythritol, lactitol, maltitol, alitame, miraculin, monellin, thaumatin, and mixture thereof, and is in an amount of from 0.05 to 0.5% w/V. 
Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je najmanje jedan zaslađivač tipa ne-šećer saharina, soli saharina, natrij saharin, kalcij saharin, sukraloze, kalij acesulfam, steviosida, steviol, manitol, eritritol, laktitola, maltitol, alitam, mirakulin, monelin, taumatin, i njihova smjesa, i primjerice odabran od saharin natrija u količini od 0.05 do 0.5% tež/vol.
The composition according to anyone of claims 1 to 10, wherein propranolol or a pharmaceutically acceptable salt thereof is propranolol hydrochloride in an amount of 0.428 or 0.57 % w/V wherein the at least one sweetener is saccharin sodium in an amount of 0.15% w/V, wherein the at least one flavouring agent is a mixture of vanilla and strawberry flavour in an amount of 0.32% w/V the at least one viscosity increasing agent is hydroxyethylcellulose in an amount of 0.35 % w/V. 
Otopina sukladno bilo kojem od patentnih zahtjeva 1 do 12, pri čemu propranolol ili njegove farmaceutski prihvatljive soli su propranolol hidroklorid u količini od 0.428 ili 0.57 % tež/vol pri čemu je najmanje jedno sladilo natrijev saharin u količini od 0.15% tež/vol, pri čemu je najmanje jedan agens za poboljšanje okusa smjesa vanilije i jagode u količini od 0.32% tež/vol i najmanje jedno sredstvo za povećanje viskoznosti je hidroksietilceluloza u količini od 0.35 % tež/zapr.
Device according to claim 1 or claim 2, wherein the first closure member (36) is also placed at the bottom end of the inner tube (26) and is arranged to cooperate with the bottom end of the outer tube (24) to open/close the first annular conduit (44) at the bottom. 
Uređaj sukladno zahtjevu 1 ili zahtjevu 2, pri čemu je prvi element za zatvaranje (36) također smješten na donji kraj unutarnje cijevi (26) i organiziran je da djeluje s donjim dijelom vanjske cijevi (24) da otvara/zatvara prvi prstenasti kanal (44) na dnu.
Device according to claim 5 or claim 6, wherein the first linear actuator (68, 70) and the second linear actuator (74, 76) are double-acting pneumatic cylinders. 
Uređaj sukladno zahtjevu 5 ili zahtjevu 6, pri čemu su prvi linearni pokretač (68, 70) i drugi linearni pokretač (74, 76) dvostruko djelujući pneumatski cilindri.
generating a biomarker comprising of one or more non-reducing end oligosaccharides, wherein the biomarker is a saturated oligosaccharide and is generated by treating a purified population of heparan sulfates isolated from a biological sample from the individual, with digesting glycosaminoglycan lyases, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIB disorder relative to individuals without the MPS IIIB disorder, and 
generiranje biomarkera koji sadrži jedan ili više oligosaharida nereducirajućeg kraja, pri čemu je biomarker zasićeni oligosaharid i generiran je tretiranjem pročišćene populacije heparan sulfata izoliranih iz biološkog uzorka pojedinca, liazama koje digestiraju glikozaminoglikane, pri čemu prije tretiranja liazom biomarker nije obilno prisutan u uzorcima pojedinaca s MPS IIIB poremećajem u odnosu na pojedince bez MPS IIIB poremećaja, i
The process of claim 1 or 2, wherein a transformed biological sample is generated by treating the purified population of heparan sulfates with the digesting glycosaminoglycan lyases in step a) of claim 1, and the process further comprises purifying a population of oligosaccharides in the transformed biological sample. 
Postupak iz patentnog zahtjeva 1 ili 2, pri čemu je generiran transformirani biološki uzorak tretiranjem pročišćene populacije heparan sulfata liazama koje digestiraju glikozaminoglikane u koraku a) iz patentnog zahtjeva 1, i postupak nadalje obuhvaća pročišćavanje populacije oligosaharida u transformiranom biološkom uzorku.
The process of claim 3, wherein the population of oligosaccharides is purified from the transformed biological sample using chromatography or electrophoresis. 
Postupak iz patentnog zahtjeva 3, pri čemu je populacija oligosaharida pročišćena iz transformiranog biološkog uzorka koristeći kromatografiju ili elektroforezu.
The process of claim 5, wherein the reducing end of the oligosaccharides in the transformed biological sample is tagged with a detectable label. 
Postupak iz patentnog zahtjeva 5, pri čemu je reducirajući kraj oligosaharida u transformiranom biološkom uzorku označen oznakom koja se može detektirati.
The process of claim 5 or 6, wherein the detectable label is a mass label, a radio label, a fluorescent label, a chromophore label, or affinity label. 
Postupak iz patentnog zahtjeva 5 ili 6, pri čemu je oznaka koja se može detektirati oznaka mase, radio oznaka, fluorescentna oznaka, kromoforna oznaka ili afinitetna oznaka.
The antibody against human FGF23 or a functional fragment thereof according to any one of claims 1-5, wherein: said functional fragment is a peptide fragment selected from the group consisting of Fab, Fab', F (ab')2, disulfide stabilized Fv (dsFv), dimerized V region (diabody), single chain Fv (scFv) and CDR. 
Funkcionalni fragment iz patentnog zahtjeva 1, pri čemu je navedeni funkcionalni fragment fragment peptida izabran iz grupe koja se sastoji od Fab, Fab', F(ab')2, disulfidom stabilizirane Fv (dsFv), dimerizirane V regije (dijatijelo), jednolančanog Fv (scFv) i CDR.
A pharmaceutical composition, comprising as an active ingredient, the antibody against human FGF23 or a functional fragment thereof according to any one of claims 1-9. 
Farmaceutski sastav, kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5.
A pharmaceutical composition which can control phosphorus metabolism and/or vitamin D metabolism by FGF23 and comprises, as an active ingredient, the antibody against human FGF23 or a functional fragment thereof according to any one of claims 1-9. A pharmaceutical composition for prevention or treatment of diseases that are associated with mineral metabolism disorders comprising as an active ingredient, the antibody against human FGF23 or a functional fragment thereof according to any one of claims 1-9. 
Farmaceutski sastav za uporabu u motodi sprječavanja ili liječenja bolesti koja je povezana s poremećajima metabolizma minerala, navedeni sastav kao aktivni sastojak sadrži protutijelo na ljudski FGF23 ili funkcionalni fragment navedenog protutijela iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu je bolest koja je povezana s poremećajima metabolizma minerala odabrana iz grupe koja se sastoji od neoplastične osteomalacije, ADHR, XLH, fibrozne displazije, sindroma McCune-Albright i autosomne recesivne hipofosfatemije.
Method according to claim1 or 2, wherein before adding the lignocellulosic biomass to the pulp container, the lignocellulosic biomass has been processed for removing protein from the lignocellulosic biomass such that the lignocellulosic biomass contains between 0 to 2% protein in dry weight. 
prije dodavanja lignocelulozne biomase u spremnik za pulpu, obrada lignocelulozne biomase zbog uklanjanja proteina iz lignocelulozne biomase kao što je lignocelulozna biomasa koja sadrži između 0 i 2% proteina u masi suhe tvari.
Method according to a preceding claim, the method comprising pre-processing of the lignocellulosic biomass, the pre-processing comprising soaking the lignocellulosic biomass in water for a soaking period of at least 1 day preferably at least 2 days. 
Metoda u skladu s patentnim zahtjevom 1, metoda obuhvaća predobradu lignocelulozne biomase, predobrada obuhvaća namakanje (6) lignocelulozne biomase (5) u vodi tijekom perioda namakanja od najmanje 1 dana, poželjno najmanje 2 dana.
at least 97% of the cells in the population express on their surfaces detectable levels of MIC A/B, 
najmanje 97 % stanica u populaciji na svojoj površini izražava uočljive razine MIC A/B,
at least 65% of the cells in the population express on their surfaces detectable levels of CD304 (Neuropilin 1), 
najmanje 65 % stanica u populaciji na svojoj površini izražava uočljive razine CD304 (neuropilin 1),
at least 51% of the cells in the population express on their surfaces detectable levels of CD178 (FAS ligand), 
najmanje 51 % stanica u populaciji na svojoj površini izražava uočljive razine CD178 (FAS ligand),
at least 11% of the cells in the population express on their surfaces detectable levels of CD289 (Toll-like receptor 9), 
najmanje 11 % stanica u populaciji na svojoj površini izražava uočljive razine CD289 (receptor 9 tipa Toll),
at least 18% of the population express on their surfaces detectable levels of CD363 (Sphingosine-1-phosphate receptor 1), 
najmanje 18 % stanica u populaciji na svojoj površini izražava uočljive razine CD363 (sfingozin-1-fosfat receptor 1),
at least 24% of the cells in the population express on their surfaces detectable levels of CD99, 
najmanje 24 % stanica u populaciji na svojoj površini izražava uočljive razine CD99,
at least 80% of the cells in the population express on their surfaces detectable levels of CD181 (C-X-C chemokine receptor type 1; CXCR1), (viii) at least 30% of the cells in the population express on their surfaces detectable levels of epidermal growth factor receptor (EGF-R), 
najmanje 80 % stanica u populaciji na svojoj površini izražava uočljive razine CD181 (C-X-C kemokin receptor tipa 1; CXCR1), (viii) najmanje 30 % stanica u populaciji na svojoj površini izražava uočljive razine receptora epidermalnog faktora rasta (EGF-R),
at least 60% of the cells in the population express on their surfaces detectable levels of CXCR2 and 
najmanje 60 % stanica u populaciji na svojoj površini izražava uočljive razine CXCR2 i
the MCs are peripheral blood mononuclear cells (PBMCs); and/or 
mononuklearne stanice su mononuklearne stanice periferne krvi (PBMC); i/ili
A population of claim 10 for use according to claim 10 or 11, wherein the population is produced using MCs obtained from the patient or an allogeneic donor. 
Populacija iz zahtjeva 10 za primjenu prema zahtjevu 10 ili 11, naznačena time, što se populacija dobiva iz mononuklearnih stanica pacijenta ili alogeneičkog davatelja.
Topical vaginal compositions in gel form comprising a colostrum fraction enriched with immunoglobulins, growth factors, chemotactic factors and antimicrobial/antiviral factors, partly in free form and partly encapsulated in mucoadhesive microbeads. 
Topikalni vaginalni pripravci u obliku gela koji sadržavaju frakciju kolostruma obogaćenu imunoglobulinima, faktorima rasta, kemotaktičnim faktorima i antimikrobnim/antivirusnim faktorima, dijelom u slobodnom obliku te dijelom kapsulirano u mukoadhezivnim mikrozrncima.
Compositions as claimed in claim 1 or 2 wherein the colostrum fraction is obtainable from bovine colostrum milked between the 5th and 6th hours after calving and treated with a process which comprises: 
Pripravci kako su prijavljeni u patentnom zahtjevu 1 ili 2, naznačeno time da se frakcija kolostruma može dobiti od kravljeg kolostruma pomuzenog između petog i šestog sata nakon teljenja na kojega je djelovano postupkom koji se sastoji od:
addition of antiseptic agents to the colostrum in sufficient concentrations to ensure sterility and apyrogenicity; 
– dodavanja antiseptičkih sredstava u kolostrum u dovoljnim koncentracijama da se osigura sterilnost i apirogenost;
Compositions as claimed in claim 1 for the use in the treatment of vaginal dryness. 
Pripravci kako su prijavljeni u patentnom zahtjevu 1 za upotrebu u liječenju vaginalne suhoće.
A process for preparing a compound as claimed in any one of Claims 1 to 23, comprising the step of coupling a compound of formula 1 with a compound of formula 2: to produce a compound of formula I; where R1-R6, a, and b are as defined in Claim 1, and P is selected from H and an amino-protecting group selected from t -butoxycarbonyl, trityl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, formyl, trimethylsilyl, and t-butyldimethylsilyl; and where the process further comprises deprotecting the compound of formula 1 when P is an amino protecting group. 
Postupak za pripravu spoja prema bio kojem od patentnih zahtjeva 1 do 23, naznačen time, da se sastoji od koraka spajanja spoja formule 1 sa spojem formule 2: [image] kako bi se dobio spoj formule I; pri čemu su R1-R6, a i b definirani u patentnom zahtjevu 1 i P je odabran od H i amino-zaštitne skupine odabrane od f-butoksikarbonila, tritila, benziloksikarbonila, 9-fluorenilmetoksikarbonila, formila, trimetilsilila i t-butildimetilsilila; te gdje se postupak dalje sastoji od skidanja zaštite spoju formule 1 pri čemu je P zaštitna amino skupina.
A compound as claimed in Claim 27, for use in treating hypertension, heart failure, or renal disease. 
Spoj prema patentnom zahtjevu 27, naznačen time, da je za uporabu u liječenju povišenog krvnog tlaka, srčanog zatajenja ili bolesti bubrega.
The compound of Claim 1, where the compound is (2S,4R) -5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxymethyl-2-methyl-4-(oxalylamino)pentanoic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj (2S,4R)-5-(5'-kloro2'-fluorobifenil-4-il) -2-hidroksimetil-2- metil-4-(oksalilamino)pentanoična kiselina ili farmaceutski prihvatljiva sol istog.
The herbicidal composition according to Claim 1 or 2, wherein the mix ratio of (1) the herbicidal sulfonylurea compound or its salt to (2) the polyoxyalkylene alkyl ether phosphate or its salt is from 13:1 to 1:10,000 by weight ratio. 
Herbicidni pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je omjer mješavine (1) spoj sulfonil ureja herbicida ili soli istog u odnosu na (2) polioksialkilen alkil eter fosfat ili soli istog od 13:1 do 1:10,000 po masenom udjelu.
The herbicidal composition according to Claim 2, wherein the mix ratio of (1) the herbicidal sulfonylurea compound or its salt to (2) the polyoxyalkylene alkyl ether phosphate or its salt is from 13:1 to 1:10,000 by weight ratio, and the mix ratio of (2) the polyoxyalkylene alkyl ether phosphate or its salt to (3) the salt is from 500:1 to 1:5 by weight ratio. 
Herbicidni pripravak u skladu s patentnim zahtjevom 2, naznačen time, da omjer mješavine (1) spoj sulfonil urej herbicida ili soli istog u odnosu na (2) polioksialkilen alkil eter fosfat ili sol istog je od 13:1 do 1:10,000 po masenom udjelu te omjer mješavine od (2) polioksialkilen alkil eter fosfat ili sol istog u odnosu na (3) sol je od 500:1 do 1:5 po masenom udjelu.
The herbicidal composition according to Claim 2, wherein (3) the salt is an inorganic salt. 
Herbicidni pripravak u skladu s patentnim zahtjevom 2, naznačen time, da (3) je sol neorganska sol.
The herbicidal composition according to Claim 5, wherein the inorganic salt is a phosphate. 
Herbicidni pripravak u skladu s patentnim zahtjevom 5, naznačen time, da je neorganska sol fosfat.
The method according to Claim 7, wherein (1) the herbicidal sulfonylurea compound or its salt and (2) the polyoxyalkylene alkyl ether phosphate or its salt are applied in a weight ratio of from 13:1 to 1:10,000. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se (1) spoj sulfonil ureja herbicida ili sol istog i (2) polioksialkilen alkil eter fosfat ili sol istog primjenjuju u masenom omjeru od 13:1 do 1:10,000.
A nucleic acid, encoding a peptide according to any one of claims 1 to 6, provided, that the peptide is not the full human protein, wherein preferably said nucleic acid is DNA, cDNA, PNA, RNA or a combination thereof, or an expression vector expressing said nucleic acid. 
Nukleinska kiselina, kodirana za peptid za uporabu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
A cytotoxic T lymphocyte (CTL) according to claim 11 for use in the treatment of cancer through killing target cells in a patient wherein said target cells aberrantly present a peptide according to claim 1 or 2. 
Citotoksični T-limfocit (CTL) u skladu s patentnim zahtjevom 11 za uporabu u liječenju karcinoma uništavanjem ciljnih stanica u pacijentu, pri čemu ciljne stanice abnormalno predstavljaju peptid u skladu sa SEQ ID br. 2.
Non-therapeutic use of the peptide according to claim 1 or 2, for the generation and development of antibodies that are specific against an MHC/peptide complex comprising said peptide. 
varijante SEQ ID br. 2 odabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF, za generiranje i razvoj protutijela koja su specifična u odnosu na kompleks MHC/peptid koji sadrži navedeni peptid.
The peptide according to any of claims 1 to 3, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). A nucleic acid, encoding a peptide according to any one of claims 1 to 4, wherein preferably said nucleic acid is DNA, cDNA, PNA, RNA or a combination thereof, or an expression vector expressing said nucleic acid. 
varijante SEQ ID br. 2 odabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF, posebno onih koje sadrže N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii). Nukleinska kiselina, kodirana za peptid za uporabu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
Use of the peptide according to claim 1 or 2 for the generation and development of antibodies that are specific against an MHC/peptide complex comprising said peptide. 
varijante SEQ ID br. 2 odabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF, za generiranje i razvoj protutijela koja su specifična u odnosu na kompleks MHC/peptid koji sadrži navedeni peptid.
A monoclonal antibody that binds to human sclerostin of SEQ ID NO: 1 with a dissociation constant of less than or equal to 1 x 10-9 M as determined by surface plasmon resonance and increases at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal; and 
Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
The monoclonal antibody of any one of claims 1 to 10 for use in improving outcomes in orthopedic procedures, dental procedures, implant surgery, joint replacement, bone grafting, bone cosmetic surgery or bone repair such as fracture healing, nonunion healing, delayed union healing or facial reconstruction. 
Monoklonsko protutijelo prema bilo koje od patentnih zahtjeva 4 -9, naznačeno time, da je za uporabu u poboljšavanju ishoda kod ortopedskih procedura, zubnih procedura, operacija usadka, zamjene zglobova, presađivanja kosti, kozmetičke operacije kosti ili reparacije poput liječenja loma, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja ili rekonstrukcije lica.
wherein (i) the regulatory RNA is selected from the group consisting of antisense ssRNA, ribozyme and decoy RNA, (ii) there is an absence from the minicells of a construct for in situ expression of the regulatory RNA, and (iii) the plurality comprises a therapeutically effective amount of the regulatory RNA. 
farmaceutski prihvatljiv nositelj istih naznačeno time da (i) regulatorna RNK je izabrana iz grupe koja se sastoji od negativnih jednolančanih RNK, ribozima i RNK-mamaca, (ii) u ministanicama nedostaje konstrukt in situ ekspresije regulatornih RNK, te (iii) pluralitet obuhvaća terapijski efektivnu količinu regultornih RNA.
The composition of claim 1, wherein the regulatory RNA is not chemically modified. 
Sastav zahtjeva 1, time naznačeno da regulatorna RNK nije kemijski modificirana.
The composition of claim 1, wherein the regulatory RNA specifically interferes with expression of a protein that contributes to drug resistance. 
Sastav zahtjeva 1, time naznačeno da regulatorna RNK posebno ometa ekspresiju proteina koji pridonosi stvaranju otpornosti na ljekove.
The composition of claim 3, wherein the protein is MRP2, BCR-ABL, STI-571 resistance-associated protein, lung resistance-related protein, cyclooxygenase-2, nuclear factor kappa, XRCC1, ERCC1, GSTP1, mutant β-tubulin, or a growth factor. 
Sastav zahtjeva 3, time naznačeno da je protein MRP2, BCR-ABL, STI-571 povezan sa stvaranjem otpornosti, LRP (lung resistance related protein), ciklooksigenaza-2, nuklearni čimbenik kapa, XRCC1, ERCC1, GSTP1, mutant β-tubulin ili čimbenik rasta.
The composition of claim 7, wherein the mammalian cell surface receptor is capable of activating receptor-mediated endocytosis of the minicell. 
Sastav zahtjeva 7, naznačeno time da je receptor površine stanica sisavaca sposoban pokrenuti receptorima posredovanu endocitozu ministanica.
The composition of claim 1, wherein the regulatory RNA is antisense ssRNA. 
Sastav zahtjeva 1, naznačeno time da regulatorna RNK je negativna jednolančana RNA.
the regulatory RNA is selected from the group consisting of antisense ssRNA, ribozyme and decoy RNA; 
regulatorna RNK je izabrana iz grupe koja se sastoji od negativnih jednolančanih RNA, ribozima i RNK-mamaca;
the plurality of minicells comprises a therapeutically effective amount of the regulatory RNA. 
pularitet ministanica koje sadrže terapeutski zadovoljavajuću količinu regulatornih RNK.
A method of delivering regulatory RNA, comprising the steps of: 
Metoda dobivanja regulatornih RNA sastoji se od sljedećih koraka: